To standardize criteria, in September 2018 CTEP published guidance on inclusion of PLWH, stating that eligibility criteria should be straightforward and focus on current or past CD4 and T cell counts, history of AIDS-defining conditions, and status of HIV treatment.8 In addition, formal protocol template language for inclusion of PLWH was recommended, advising investigators to state that “HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible”8 (eTable in the Supplement). The gene discussed is CD4; the disease is AIDS.